Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate – The Motley Fool Australia
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Home / Coronavirus News / AstraZeneca COVID-19 vaccine trial data results in revised efficacy rateThe Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following…
-
Noosa News24 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs
-
Noosa News16 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
General20 hours agoWallaroos fall to Black Ferns 37-12 in Wellington Test
-
General18 hours agoCalifornia worker dead and hundreds arrested after cannabis farm raid